# This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.

> **NCT07249879** · PHASE1 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 55 (estimated)

## Conditions studied

- Relapsed/Refractory Small Cell Lung Cancer

## Interventions

- **DRUG:** GC511B CAR-T Cell Injection

## Key facts

- **NCT ID:** NCT07249879
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-03
- **Primary completion:** 2026-11-10
- **Final completion:** 2028-12-10
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2026-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07249879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07249879, "This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT07249879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*